Design of CD40 Agonists and Their Use in Growing B Cells for Cancer Immunotherapy

REFERENCES

• Clark EA, Ledbetter JA. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A. 1986;83:4494–4498.
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles: roles of T cell–B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol. 1992;149:3817–3826.
   PubMed Web of Science ®Google Scholar
• Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 1992;89:6550–6554.
   Google Scholar
• Lane P, Traunecker A, Hubele S, Inui S, Lanzavecchia A, Gray D. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol. 1992;22:2573–2578.
   Google Scholar
• Allen RC, Armitage RJ, Conley ME, CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259:990–993.
   Google Scholar
• Aruffo A, Farrington M, Hollenbaugh D, The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 1993;72:291–300.
   Google Scholar
• Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474–478.
   Google Scholar
• Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478–480.
   Google Scholar
• Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature. 1998;393:480–483.
   Google Scholar
• Lanzavecchia A. Immunology: licence to kill. Nature. 1998;393:413–414.
   Google Scholar
• Mackey MF, Barth RJ, Jr., Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol. 1998;63:418–428.
   Google Scholar
• Mackey MF, Gunn JR, Ting PP, Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res. 1997;57:2569–2574.
   Google Scholar
• Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997;8:1935–1943.
   Google Scholar
• Nakajima A, Kodama T, Morimoto S, Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol. 1998;161:1901–1907.
   Google Scholar
• van Mierlo GJ, den Boer AT, Medema JP, CD40 stimulation leads to effective therapy of CD40(–) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A. 2002;99:5561–5566.
   Google Scholar
• Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol. 2004;173:5923–5928.
   Google Scholar
• Vonderheide RH, Dutcher JP, Anderson JE, Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19:3280–3287.
   Google Scholar
• Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther. 2007;2:61–65.
   Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876–883.
   Google Scholar
• NCI. National Cancer Institute Immunotherapy Agent Workshop, July 12, 2007. 2007: Available from: http:// web.ncifcrf.gov / research / brb / workshops / NCI%20Immunotherapy % 20Workshop % 207 - 12-07.pdf
   Google Scholar
• Bajorath J, Marken JS, Chalupny NJ, Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry. 1995;34:9884–9892.
   Google Scholar
• Bajorath J. Detailed comparison of two molecular models of the human CD40 ligand with an x-ray structure and critical assessment of model-based mutagenesis and residue mapping studies. J Biol Chem. 1998;273:24603–24609.
   Google Scholar
• Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science. 1995;267:1494–1498.
   Google Scholar
• Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J Immunol. 1996;156:2345–2348.
   Google Scholar
• Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Med Biol. 2007;597:131–151.
   Google Scholar
• Schneider P, Holler N, Bodmer JL, Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187:1205–1213.
   Google Scholar
• Siegel RM, Muppidi JR, Sarker M, SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol. 2004;167:735–744.
   Google Scholar
• Hanks BA, Jiang J, Singh RA, Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med. 2005;11:130–137.
   Google Scholar
• Heath AW, Chang R, Harada N, Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. Cell Immunol. 1993;152:468–480.
   Google Scholar
• Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science. 1991;251:70–72.
   Google Scholar
• White AL, Chan HT, Roghanian A, Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol. 2011;187:1754–1763.
   Google Scholar
• Wilson NS, Yang B, Yang A, An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 2011;19:101–113.
   Google Scholar
• Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333:1030–1034.
   Google Scholar
• Smyth MJ, Kershaw MH. Immunology: the adjuvant effects of antibodies. Science. 2011;333:944–945.
   Google Scholar
• Haswell LE, Glennie MJ, Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol. 2001;31:3094–3100.
   Google Scholar
• Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13:1083–1088.
   Google Scholar
• Morris AE, Remmele RL Jr, Klinke R, Macduff BM, Fanslow WC, Armitage RJ. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem. 1999;274:418–423.
   Google Scholar
• Matsuura JE, Morris AE, Ketchem RR, Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: evidence of a reversible acid-denatured molten globule. Arch Biochem Biophys. 2001;392:208–218.
   Google Scholar
• Guo Z, Eisenberg D. Runaway domain swapping in amyloid-like fibrils of T7 endonuclease I. Proc Natl Acad Sci U S A. 2006;103:8042–8047.
   Google Scholar
• Fan X, Upadhyaya B, Wu L, CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. Clin Immunol. 2012;143:152–161.
   Google Scholar
• Jain A, Kovacs JA, Nelson DL, Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood. 2011;118:3811–3817.
   Google Scholar
• Holler N, Tardivel A, Kovacsovics-Bankowski M, Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428–1440.
   Google Scholar
• Stone GW, Barzee S, Snarsky V, Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol. 2006;80:1762–1772.
   Google Scholar
• Miconnet I, Pantaleo G. A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. Vaccine. 2008;26:4006–4014.
   Google Scholar
• Schultze JL, Michalak S, Seamon MJ, CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100:2757–2765.
   Google Scholar
• Janeway CA, Jr., Ron J, Katz ME. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol. 1987;138:1051–1055.
   Google Scholar
• Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology. 2008;124:129–140.
   Google Scholar
• Lee J, Dollins CM, Boczkowski D, Sullenger BA, Nair S. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology. 2008;125:229–240.
   Google Scholar
• Wu C, Liu Y, Zhao Q, Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: a preliminary approach for anti-HBV immunotherapy. Virol J. 2010;7:370.
   Google Scholar
• Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood. 2004;103:2046–2054.
   Google Scholar
• von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002;99:3319–3325.
   Google Scholar
• Kondo E, Gryschok L, Schultze JL, von Bergwelt-Baildon MS. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens. J Immunother. 2009;32:157–160.
   Google Scholar
• Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003;63:2836–2843.
   Google Scholar
• Tu W, Lau YL, Zheng J, Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood. 2008;112:2554–2562.
   Google Scholar
• Mathieu M, Cotta-Grand N, Daudelin JF, CD40-activated B cells can efficiently prime antigen-specific naive CD8+ T cells to generate effector but not memory T cells. PloS One. 2012;7:e30139.
   Google Scholar
• Kretschmer B, Kuhl S, Fleischer B, Breloer M. Activated T cells induce rapid CD83 expression on B cells by engagement of CD40. Immunol Lett. 2011;136:221–227.
   Google Scholar
• Blair PA, Chavez-Rueda KA, Evans JG, Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol. 2009;182:3492–3502.
   Google Scholar
• Morva A, Lemoine S, Achour A, Pers JO, Youinou P, Jamin C. Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood. 2012;119:106–114.
   Google Scholar
• Schioppa T, Moore R, Thompson RG, B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A 2011;108:10662–10667.
   Google Scholar
• Iwata Y, Matsushita T, Horikawa M, Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117:530–541.
   Google Scholar
• Mauri C, Ehrenstein MR. The ‘short’ history of regulatory B cells. Trends Immunol. 2008;29:34–40.
   Google Scholar
• Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627–630.
   Google Scholar
• Wijesuriya R, Maruo S, Zou JP, B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state. Int Immunol. 1998;10:1057–1065.
   Google Scholar
• Olkhanud PB, Damdinsuren B, Bodogai M, Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res. 2011;71:3505–3515.
   Google Scholar
• von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006;107:2786–2789.
   Google Scholar
• Kondo E, Gryschok L, Klein-Gonzalez N, CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol. 2009;155:249–256.
   Google Scholar
• Sorenmo KU, Krick E, Coughlin CM, CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PloS One. 2011;6:e24167.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422.
   Google Scholar